KOSPIBiotech & Pharma002210

Dongsung Pharmaceutical

₩1,014▼ 0.59%2026-11-18 close
Market Cap
₩98B
Turnover
₩39,513,300
Volume
40K
Shares out.
96.6M
PER
—
PBR
1.7×
EPS
-₩571
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

After recapitalization, earnings recovery is the test

Dongsung Pharmaceutical has moved past the first stage of its financial restructuring after roughly KRW 160 billion of new funding and reported court approval to close its rehabilitation proceedings, but disclosed results still show losses, with a KRW 10.1 billion operating loss in 2025 and a KRW 28 billion controlling-shareholder net loss in the third quarter of 2026.

  1. 1

    Revenue fell for three straight years through 2025 to KRW 87.2 billion, and the operating loss widened to KRW 10.1 billion.

  2. 2

    After court approval of the rehabilitation plan on March 27, 2026, the company raised KRW 70 billion through a rights-type capital increase and KRW 50 billion through convertible bonds, and press reports in May 2026 described the closing of the proceedings.

  3. 3

    The first quarter of 2026 returned to a small operating profit, but the second and third quarters posted operating losses, and the controlling-shareholder net loss over the last four quarters totals KRW 39.6 billion.

  4. 4

    A disclosure made on November 16, 2026 showed a cumulative derivative valuation loss of KRW 25.87 billion for January to September 2026, which the company described as a non-cash accounting loss.

  5. 5

    The debt-to-equity ratio reached 620.7% at the end of 2025, up from 151.6% in 2022, with total equity of KRW 23.4 billion against total liabilities of KRW 145.1 billion.

02

Business structure

Dongsung Pharmaceutical, founded in 1957, is a mid-sized pharmaceutical company that reports three business segments: pharmaceuticals, hair dye, and cosmetics.

Its flagship pharmaceutical product is the antidiarrheal Jeongrohwan, supported by long-established brands such as the hair-loss treatment Dong Sung Minoxidil and the insecticide Biokill.

The company is described as a leading brand in Korea's hair-dye market, which traces its origins to the country's first home hair dyes.

According to a Medicopharma report on the first quarter of 2026, hair dye sales reached KRW 6.1 billion, about 32% of total revenue, followed by hair-loss products at KRW 2.7 billion, motion-sickness medicine at KRW 1.7 billion, and digestive and antidiarrheal products at KRW 1.4 billion.

The same report put first-quarter sales of the pharmaceutical and hair-dye segment at KRW 17.8 billion with an operating profit of KRW 300 million, and cosmetics sales at KRW 1.3 billion with an operating loss of KRW 900 million.

The cosmetics segment lost KRW 1.0 billion on KRW 5.7 billion of sales in 2025, and its small share of revenue has still weighed on profitability. The company plans to cut low-margin products and concentrate on core items.

Its anticancer candidate Pono-gen, a photosensitizer-based pipeline targeting pancreatic and peritoneal cancers, was in Phase 2 clinical trials according to 2026 reports. Production runs at a plant in Asan, Chungcheongnam-do, where utilization was 92% in the first quarter of 2026, close to 94% in 2025.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩21.8B₩400M1.9%
2025Q4₩19.1B-₩7.1B−37.3%
2026Q1₩19.1B₩300M1.5%
2026Q2₩22.1B-₩2B−9.2%
2026Q3₩19.8B-₩1.7B−8.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩93.3B-₩3.1B-₩2.1B−3.3%−5.0%151.6%
2023₩88.6B₩600M-₩2.1B0.7%−5.2%188.9%
2024₩88.4B-₩5.7B-₩14.6B−6.5%−33.1%219.9%
2025₩87.2B-₩10.1B-₩25.7B−11.6%−110.1%620.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue fell from KRW 93.3 billion in 2022 to KRW 88.6 billion in 2023 (down 5.1% year on year), KRW 88.4 billion in 2024 (down 0.2%), and KRW 87.2 billion in 2025 (down 1.4%).

Revenue declined for three consecutive years from 2023 through 2025, with 2022 the largest year and 2025 the smallest within the 2022 to 2025 period. A 2024 press report described the 2022 revenue as a record high.

Operating results swung from an operating loss of KRW 3.1 billion in 2022 to an operating profit of KRW 596 million in 2023, then back to an operating loss of KRW 5.73 billion in 2024. The 2025 operating loss widened to KRW 10.1 billion, making 2024 and 2025 two consecutive loss years.

Operating margin was -3.3% in 2022, 0.7% in 2023, -6.5% in 2024, and -11.6% in 2025. The controlling-shareholder net loss narrowed from KRW 2.12 billion in 2022 to KRW 2.07 billion in 2023, then widened to KRW 14.6 billion in 2024 and KRW 25.7 billion in 2025, which is four consecutive loss years.

An April 2026 press report said net income has been in the red for ten consecutive years. Net loss including non-controlling interests was disclosed at the same values as the controlling-shareholder net loss in each year.

The company previously said its 2024 results reflected a big bath, with long-term receivables written off and surplus inventory cleared. Total equity at the end of 2025 was KRW 23.4 billion, below total liabilities of KRW 145.1 billion, and the debt-to-equity ratio rose from 151.6% in 2022 to 620.7% in 2025.

An April 2026 press report said impairment losses of KRW 12.7 billion were recognized on receivables other than trade receivables. Operating cash flow went from negative KRW 3.88 billion in 2022 to negative KRW 12.9 billion in 2025.

Quarterly results show that the third quarter of 2025 posted an operating profit of KRW 411 million before the fourth quarter swung to an operating loss of KRW 7.12 billion. The first quarter of 2026 returned to an operating profit of KRW 289 million on revenue of KRW 19.1 billion.

Operating losses of KRW 2.03 billion in the second quarter and KRW 1.73 billion in the third quarter of 2026 make two consecutive loss quarters, and the third-quarter controlling-shareholder net loss was KRW 28 billion.

A disclosure made on November 16, 2026 showed a cumulative derivative valuation loss of KRW 25.87 billion for January to September 2026, which the company described as a non-cash accounting loss. Press reports tied this loss to convertible bonds.

05

Industry analysis

Over-the-counter medicines, the core market for Dongsung Pharmaceutical, benefit from rising demand as the population ages. Pricing policy on drugs, however, is cited as a drag on sales.

A half-year 2026 commentary, compiled by WiseReport as of September 3, 2026, said pharmaceuticals and hair dye made up 97% of sales, and that sales declined because of drug price cuts and intensified discounting in cosmetics. The same commentary said cost reductions narrowed the operating loss.

The hair-loss treatment market is competitive, yet an older press report noted steady growth for Dong Sung Minoxidil. The hair-dye market is led by a company that holds one of the earliest domestic dye brands, while cosmetics faces intensifying discount competition.

With annual revenue below KRW 100 billion, the company is a small mid-sized pharmaceutical player. Utilization at the Asan plant was 92% in the first quarter of 2026, close to 94% in 2025, which indicates normal operating levels.

In anticancer drug development, outcomes depend on clinical results and access to funding, so the Phase 2 data for Pono-gen is the main variable for comparison.

Large listed biotech companies such as Samsung Biologics and Alteogen emphasize contract manufacturing or platform technology, whereas Dongsung Pharmaceutical's model is closer to a traditional OTC and hair-care pharmaceutical business.

After the Taekwang-led consortium took control in 2026, the plan to expand sales through group home-shopping and media-commerce channels drew attention from the industry.

06

Outlook

The company's main growth pillars are the anticancer candidate Pono-gen, existing over-the-counter brands in hair dye and hair loss, and channel expansion after the Taekwang-led consortium took control.

Pono-gen was in Phase 2 clinical trials according to 2026 reports, and the company previously projected approval in 2027. Changes in clinical results or the approval timeline would change the outlook for the drug.

Press reports said the consortium's group home-shopping and media-commerce channels could be used to expand sales, and that research spending may increase. In 2026 the company said it would cut low-margin items and focus the portfolio on core products such as Jeongrohwan and Dong Sung Minoxidil.

It also plans to raise the share of online sales and reduce reliance on offline distribution. Of the KRW 50 billion convertible bond, KRW 40 billion is earmarked for operating funds including facility investment, and KRW 10 billion for repaying rehabilitation claims.

The conversion price is KRW 1,000, and disclosed conversion period runs from April 13, 2027 to March 13, 2029, while another report gave April 9, 2027 as the start date. An April 2026 press analysis said full conversion could add about 50 million new shares.

An immediate appeal against the court's approval of the rehabilitation plan was disclosed on April 8, 2026, and the company said it will respond through its legal representatives. The next checkpoint is how the 2026 annual report presents full-year operating margin and debt-to-equity ratio.

07

Valuation

PER
—
PBR
1.7×
ROE
-79.1%
EPS
-₩571
BPS
₩618
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the company posted net losses over the last four quarters. The company pays no dividend, so comparing its dividend yield with the industry average has limited meaning.

The price-to-book ratio should be read against a book value that has shrunk, with equity below paid-in capital at the end of 2025 under partial capital impairment, a structure that press reports said persisted even after the capital raise.

Market capitalization should be read alongside the possibility of new shares from the convertible bonds. The decline in operating margin from -3.3% in 2022 to -11.6% in 2025 is the most direct factual reference for profitability.

Within 2022 to 2025, only 2023 was a profitable year, so whether first-quarter 2026's return to profit carries into full-year results is the basis for future comparison.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

A base of established brands

Long-established brands such as Jeongrohwan, Dong Sung Minoxidil, and the hair-dye line support a large share of revenue. In the first quarter of 2026, hair-dye sales reached KRW 6.1 billion, about 32% of total revenue.

The pharmaceutical and hair-dye segment posted an operating profit of KRW 300 million in the same quarter. Trimming low-margin products could leave room to improve margins, according to press assessments.

Financial restructuring and funding

After court approval of the rehabilitation plan on March 27, 2026, the company raised KRW 70 billion through a capital increase and KRW 50 billion through convertible bonds. Press reports in May 2026 described the application and approval to close the rehabilitation proceedings.

A clean audit opinion has partly resolved the grounds for designation as a managed stock, according to a press report. The largest shareholder changed to a consortium led by a turnaround fund and a Korean chemicals group, which reshaped management.

A profitable quarter and a drug pipeline

The first quarter of 2026 returned to a quarterly operating profit of KRW 289 million. Pono-gen was in Phase 2 clinical trials according to 2026 reports. The company previously projected approval in 2027. Research spending increases are under review after the change in control.

09

Bear factors

Shrinking sales and wider losses

Revenue declined for three consecutive years from 2023 through 2025 to KRW 87.2 billion. The 2025 operating loss reached KRW 10.1 billion, and the controlling-shareholder net loss widened to KRW 25.7 billion. The 2025 operating margin of -11.6% was the lowest in the 2022 to 2025 period. An April 2026 press report said net income has been in the red for ten consecutive years.

Capital erosion and high leverage

The debt-to-equity ratio rose from 151.6% in 2022 to 620.7% in 2025. Total equity was KRW 23.4 billion and total liabilities were KRW 145.1 billion at the end of 2025. An April 2026 press report said KRW 12.7 billion of impairment was recognized on receivables other than trade receivables.

Partial capital impairment, with equity below paid-in capital, reportedly persisted even after the capital raise.

Derivative valuation losses and a quality issue

A disclosure made on November 16, 2026 showed a cumulative derivative valuation loss of KRW 25.87 billion for January to September 2026. The company described it as a non-cash accounting loss.

Press reports said some batches of a motion-sickness medicine, Tosrong S solution, were voluntarily recalled after the main ingredient content fell outside the standard. The controlling-shareholder net loss for the third quarter of 2026 was KRW 28 billion.

10

Risk factors

Financial and liquidity

An April 2026 press report said the borrowing dependence ratio jumped from 103% to 270%. Interest and redemption terms on the KRW 50 billion convertible bond remain a burden. Operating losses in 2024 and 2025 could increase the need for additional funding. Whether capital impairment is resolved depends on how quickly operations recover.

Legal and listing

An immediate appeal against the court's approval of the rehabilitation plan was disclosed on April 8, 2026, and the final outcome awaits further ruling. The company said it will respond through legal representatives.

Reports on the listing-suitability review and trading suspension have described the situation differently. Timing of any resumption of trading will be fixed only after an exchange disclosure.

Quality, regulation, and dilution

Press reports of a voluntary recall of some Tosrong S solution batches highlighted quality-control pressure. Drug price policy can keep affecting OTC pricing and margins. A 2026 press analysis said full conversion of the convertible bonds would add about 50 million new shares, diluting existing shareholders.

11

What to watch next

  1. Around March 31, 2027 (annual report filing deadline)

    The 2026 annual report will show whether the decline in annual revenue continues and how operating margin and total equity are presented.

  2. Around May 15, 2027 (first-quarter report filing deadline)

    The first-quarter 2027 results will show whether the operating profit of early 2026 holds and whether operating losses seen since the second quarter of 2026 narrow.

  3. From April 13, 2027 (start of conversion period, per disclosure)

    The relationship between the KRW 1,000 conversion price and the share price, together with the number of new shares, will determine the extent of dilution for existing shareholders.

  4. During 2027 (company target timeframe)

    Phase 2 results for Pono-gen and any marketing approval application will show whether the 2027 approval outlook from earlier reports holds.

12

Overall view

Dongsung Pharmaceutical is a mid-sized drugmaker with long-established OTC brands and an anticancer pipeline, but its disclosed results have not yet reached a recovery stage. Revenue fell from KRW 93.3 billion in 2022 to KRW 87.2 billion in 2025, and the 2025 operating margin was -11.6%.

After an operating profit in the first quarter of 2026, operating losses followed in the second and third quarters, and the controlling-shareholder net loss over the last four quarters totals KRW 39.6 billion.

About KRW 160 billion of new funding and a change in largest shareholder and management came through the rehabilitation process, yet total equity of KRW 23.4 billion remains below total liabilities of KRW 145.1 billion.

The derivative valuation loss and the motion-sickness medicine recall disclosed in November 2026 added items to monitor on both finances and quality.

Strengths are the revenue base of established brands and Pono-gen's Phase 2 progress, while weaknesses are consecutive losses, high leverage, and possible dilution from the convertible bonds.

The next checkpoint is the 2026 annual report, followed by first-quarter 2027 results and the conversion period starting in April 2027. This report is for information only and does not include an investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. app.rndcircle.io
  2. dailypharm.com
  3. newstopkorea.com
  4. medicopharma.co.kr
  5. comp.wisereport.co.kr
  6. medipana.com
  7. k-health.com
  8. thebionews.net
  9. topdaily.kr
  10. koreastocknews.com
  11. dailypharm.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. m.news.nate.com
  18. biz.newdaily.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis